Pacira BioSciences

Yahoo Finance • 7 hours ago

PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Feb. 02, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. (“Paci... Full story

Yahoo Finance • 2 days ago

PCRX Stockholders Should Contact Shareholder Rights Firm Robbins for Information About the Class Action Against Pacira BioSciences, Inc.

SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Pacira BioSciences, Inc. (NASDAQ: PCRX) securities betwee... Full story

Yahoo Finance • 2 days ago

Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Pacira Biosciences, Inc. (“Pacira” or the “... Full story

Yahoo Finance • 3 days ago

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclus... Full story

Yahoo Finance • 3 days ago

PCRX LAWSUIT ALERT: Levi & Korsinsky Notifies Pacira BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to rec... Full story

Yahoo Finance • 4 days ago

Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights – PCRX

NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Shareholders who purchased shares of PCRX during the class period listed are encourag... Full story

Yahoo Finance • 4 days ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Pacira To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Pacira between August 2,... Full story

Yahoo Finance • 6 days ago

ROSEN, A LEADING LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX

NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclus... Full story

Yahoo Finance • 6 days ago

Pacira BioSciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights – PCRX

NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to rec... Full story

Yahoo Finance • 9 days ago

ROSEN, LEADING INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX

NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclus... Full story

Yahoo Finance • 11 days ago

Shareholders that lost money on Pacira BioSciences, Inc. (PCRX) should contact Levi & Korsinsky about pending Class Action - PCRX

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to rec... Full story

Yahoo Finance • 12 days ago

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Pacira To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Pacira between August 2,... Full story

Yahoo Finance • 12 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira Lawsuit – PCRX

NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Shareholders who purchased shares of PCRX during the class period listed are encourag... Full story

Yahoo Finance • 16 days ago

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX

NEW YORK, Jan. 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between... Full story

Yahoo Finance • 16 days ago

PCRX Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Shareholders of the Class Action Lawsuit Against Pacira BioSciences, Inc.

SAN DIEGO, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Pacira BioSciences, Inc. (NASDAQ: PCRX) securities betwe... Full story

Yahoo Finance • 20 days ago

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Pacira BioSciences, Inc. Securities and Sets a Lead Plaintiff Deadline of March 14, 2025

NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Pacira BioSciences, Inc. (“Pacira” or the “Com... Full story

Yahoo Finance • 6 months ago

Pacira BioSciences Reports Second Quarter 2024 Financial Results

Pacira BioSciences -- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative h... Full story

Yahoo Finance • 9 months ago

Earnings Miss: Pacira BioSciences, Inc. Missed EPS By 17% And Analysts Are Revising Their Forecasts

Investors in Pacira BioSciences, Inc. (NASDAQ:PCRX) had a good week, as its shares rose 9.3% to close at US$29.86 following the release of its quarterly results. It was not a great result overall. While revenues of US$167m were in line wit... Full story

Yahoo Finance • 11 months ago

Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results

Pacira BioSciences — Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $214 million — — EXPAREL surpasses the 14 million patient mark — — Conference call today at 8:30 a.m. ET —... Full story

Yahoo Finance • last year

Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — — New indications for use as an adductor canal block and sciatic nerve block in... Full story